stockrow
Friday 6 November 2026
Export KOD’s income statement to Excel — free account
Kodiak Sciences Inc.
- EPS
- −1.94%
- Free cash flow
- −33.9%
Quarter to June 2026, against a year earlier
98.85
7.83
+8.60%
Follow KOD
Alert me
Kodiak Sciences Inc. (KOD) EPS (diluted)
Kodiak Sciences Inc.'s EPS (diluted) for fiscal 2025 was −$4.32, compared with −$3.35 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$4.19. Over the past ten years it has ranged from −$6.39 (fiscal 2022) to −$1.25 (fiscal 2019); the current reading is higher than 40% of that period. Kodiak Sciences Inc. ranks 419th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$4.32 | — |
| FY2024 | −$3.35 | — |
| FY2023 | −$4.97 | — |
| FY2022 | −$6.39 | — |
| FY2021 | −$5.16 | — |
| FY2020 | −$2.91 | — |
| FY2019 | −$1.25 | — |
| FY2018 | −$2.77 | — |
| FY2017 | −$3.72 | — |
| FY2016 | −$2.38 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.05 | — |
| Mar 2026 | −$0.94 | — |
| Dec 2025 | −$1.04 | — |
| Sep 2025 | −$1.16 | — |
| 31 more quarters | Free account |
Against its own ten years
Low −$6.39
High −$1.25
Ten-year median
−$3.53
Current reading's percentile
40
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $2.24 |
| PTCT PTC Therapeutics, Inc. compare | −$1.40 |
| ORKA Oruka Therapeutics, Inc. compare | −$2.12 |
| CGON CG Oncology, Inc. compare | −$2.69 |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$2.73 |
| IMVT Immunovant, Inc. compare | −$2.82 |
| IONS Ionis Pharmaceuticals, Inc. compare | −$3.46 |
| KOD Kodiak Sciences Inc. | −$4.19 |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$15.22 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item